Slow taper of semaglutide may help keep weight off after stopping

NCT ID NCT07294950

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at what happens when people stop taking the weight-loss drug semaglutide. Researchers want to see if slowly reducing the dose over 16 weeks helps maintain weight loss and heart health better than stopping all at once. The study involves 98 adults with obesity who have already lost at least 10% of their body weight on semaglutide. Participants will be randomly assigned to either gradually lower their dose or stop immediately, and their weight, blood pressure, and appetite hormones will be tracked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
semaglutide
What this could lead to
If successful, this could show that a gradual reduction of semaglutide helps people keep off more weight and maintain heart health after stopping the drug.
What could go wrong
This is a small, early-phase study with only 98 participants. It focuses on short-term effects after stopping the drug, so long-term weight maintenance or health benefits are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APPETITE REGULATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Body Weight Changes Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Leadership Sinai Centre for Diabetes

    RECRUITING

    Toronto, Ontario, M5T 3L9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.